Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic triple-negative breast cancer.
The biopharmaceutical company on Monday said that the results of the Ascent-04/Keynote-D19 study demonstrated that Trodelvy and Keytruda significantly improved progression-free survival, or how long the patients lived without the disease worsening, when compared to Keytruda and chemotherapy.
"These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer," Chief Medical Officer Dietmar Berger said.
Gilead said overall survival, a key secondary endpoint, was not mature at the time of the analysis for progression-free survival but there was an early trend in improvement of that endpoint with the Trodelvy-Keytruda drug combination.
Triple-negative breast cancer whose tumors express PD-L1 is the most aggressive type of breast cancer and has historically been difficult to treat, accounting for about 15% of all breast cancers, the company said.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.